Biogen is a U.S. biotechnology company engaged in the research, development and commercialization of therapies for serious neurological and related diseases. Its research activities span several medicinal modalities, including biologics and other targeted approaches, supported by clinical-development and commercial capabilities. The company is headquartered in Cambridge, Massachusetts, and its shares trade on Nasdaq under BIIB. Biogen has a long-standing focus on neuroscience, while its clinical and commercial activities also extend into immunology and selected rare diseases.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Biogen is a U.S. biotechnology company engaged in the research, development and commercialization of therapies for serious neurological and related diseases. Its research activities span several medicinal modalities, including biologics and other targeted approaches, supported by clinical-development and commercial capabilities. The company is headquartered in Cambridge, Massachusetts, and its shares trade on Nasdaq under BIIB. Biogen has a long-standing focus on neuroscience, while its clinical and commercial activities also extend into immunology and selected rare diseases.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
Business, technology & evidence
2025-11-24Biogen and Dayra partner on oral macrocyclic peptides with $50 million upfront
Biogen is a U.S. biotechnology company engaged in the research, development and commercialization of therapies for serious neurological and related diseases. Its research activities span several medicinal modalities, including biologics and other targeted approaches, supported by clinical-development and commercial capabilities. The company is headquartered in Cambridge, Massachusetts, and its shares trade on Nasdaq under BIIB. Biogen has a long-standing focus on neuroscience, while its clinical and commercial activities also extend into immunology and selected rare diseases.
SecuritiesNasdaq: BIIB
Program / service
Target / indication
Representative stage
Evidence & scope
Biogen–Dayra oral macrocycles in immunology
Not disclosed · Not disclosed
未披露
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Biogen and Dayra announced a research collaboration to discover and optimize oral macrocyclic peptides for immunological targets. Dayra receives $50 million upfront and may receive candidate-acquisition payments and development milestones per program. Biogen would lead subsequent development, manufacturing, and potential commercialization. The agreement concerns early discovery rather than established clinical efficacy.
